Navigation Links
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Date:7/18/2014

NORTH CHICAGO, Ill., July 18, 2014 /PRNewswire/ -- AbbVie Inc. ("AbbVie") will hold an analyst and investor call in respect of the recommended combination of AbbVie with Shire plc today at 8am CDT/2pm BST. A live webcast will be available from www.abbvieinvestor.com.

DIAL IN INFORMATION 
U.K. toll free : 0800-279-9630
U.S. toll free : 866-617-1526
International: 001-210-795-0624
Passcode: AbbVie

In accordance with Rule 30.4 of the Takeover Code, a copy of this announcement will be available on AbbVie's website at http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents.  A further announcement will be made as appropriate.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in January 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. AbbVie is traded on the New York Stock Exchange under "ABBV". Additional information is available on the company's website at www.abbvieinvestor.com.

The directors of AbbVie accept responsibility for the information contained in this document and, to the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and it does not omit anything likely to affect the import of such information.

Further information

J.P. Morgan Securities LLC ("J.P. Morgan"), togethe
'/>"/>

SOURCE AbbVie Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
2. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
3. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
4. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
5. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
6. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
7. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
8. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
11. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Sutro Biopharma today ... as one of 2014,s Fierce 15 biotechnology companies, ... biotechnology companies in the industry.  "Sutro ... of backers as well as industry partners for what ... conjugates and bispecifics," says John Carroll , editor ...
(Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... Chinese Diclofenac Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2
... Boston Scientific Corporation (NYSE: BSX ) today announced ... the "Donald S. Baim, M.D., ,75 Scholarship Fund" for Yale ... interventional cardiology pioneer and Yale School of Medicine graduate who ... 2006 until 2009, when he died unexpectedly. ...
... DEERFIELD, Ill., Feb. 15, 2011 Takeda Pharmaceuticals ... Company Limited, today announced that its Pharmaceutical Development ... (NYSE: CVD ) and Quintiles, two ... Under terms of the agreements, Covance ...
Cached Medicine Technology:Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 2Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 3Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 4Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles 2
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... Scans of young children,s brains might help predict ... potentially allow doctors to identify those with dyslexia ... suggests. "Early identification and interventions are extremely ... most neurodevelopmental disorders," the study,s senior author, Dr. ... adolescent psychiatry at University of California, San Francisco ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The struggles ... English proficiency (LEP) patients has been well-documented—reportedly, language barriers ... repeat visits to the emergency room and an increased ... , At Sanford Health, the largest medical facility ... a rising LEP population necessitated the need for ...
(Date:9/22/2014)... Tenn. (PRWEB) September 22, 2014 ... contact center and customer service solutions. , WHAT: ... is focused on customer care for the connected ... landscapes continue to offer new challenges and opportunities ... to helping attendees identify best practices, network and ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... is associated with an increased risk of heart failure and ... concludes a study published on bmj.com today. ... continued use of rosiglitazone for most patients. Rosiglitazone and ... are widely used for the treatment of type 2 diabetes. ...
... year, 500,000 project to co-ordinate European and international ... treat malaria. The CRIMALDDI project (Coordination, Rationalisation ... Initiatives) is being led by the Liverpool School ... players in the antimalarial drug discovery fields including ...
... Having 45 million doses by Oct. 15 will still be ... Health experts do not believe that the delay in receiving ... protect Americans against the newly circulating virus. , But having ... than the originally anticipated 120 million doses, does throw a ...
... , MONROVIA, Calif., Aug. 20 STAAR Surgical Company ... minimally invasive ophthalmic products, today reported on the status of its application ... , , As anticipated, the Ministry of Health, Labour ... in Japan, at which time the STAAR Visian ICL products were considered ...
... ... and innovative charitable program that provides free hair restoration services to children suffering from ... ... , the world,s first online social network community dedicated to all-things hair loss has ...
... ... Sparsense, the developer of a novel image and signal processing ... firm. The exclusive partnership will allow the development of various custom ... applications. The new technology can be applied to MRI, MR video ...
Cached Medicine News:Health News:Diabetes drug linked to increased risk of heart failure 2Health News:LSTM to lead EU project to coordinate antimalarial drug research 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 2Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 4Health News:Hair Loss Website Launches Program for Children 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: